Landos Biopharma Inc (LABP) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access LABP Annual Balance Sheets →
Reviewing balance sheet data across recent quarters allows users to assess how Landos Biopharma Inc manages assets, liabilities, and equity through different cycles.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2024)
(Dec 31 2023) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Assets
Cash & cash equivalent29.00
Marketable Securities, Current SH0.00
Cash & Short-term Investments29.00
Other Current Assets0.00
Prepaid Expense, Current AS0.84
Total Current Assets29.90
Restricted Cash0.05
Total Assets29.90
Liabilities
Accounts Payable, Current AC1.57
Accrued Liabilities, Current AC5.18
Other Liabilities, Current0.00
Total Current Liabilities6.74
Total Long-term Debt0.00
Total Liabilities6.74
Stockholders' Equity
Common Stock Value0.03
Additional Paid In Capital Common Stock187.38
Retained Earnings / Accumulated Deficit-164.26
Accumulated Other Comprehensive Income0.00
Other Equity0.00
Common Stockholder's Equity23.15
Total Stockholder's Equity23.15
Liabilities & Stockholder's Equity29.90
4 historic quarters locked

Sign in to unlock the full Landos Biopharma Inc balance sheet history.

About Landos Biopharma Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-24-056311

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.